Published in Antivir Ther on October 12, 2015
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks | NCT01218802
Heart fat in HIV: marker or mediator of risk? Curr Opin HIV AIDS (2017) 0.75
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis (2011) 2.35
Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis (2009) 2.24
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis (2014) 1.86
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care (2010) 1.86
Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther (2010) 1.83
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS (2014) 1.46
Hyperhomocysteinemia as a risk factor for ischemic heart disease. J Coll Physicians Surg Pak (2004) 1.43
Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis (2013) 1.36
Metabolic complications of HIV therapy in children. AIDS (2004) 1.28
Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther (2011) 1.28
Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr (2008) 1.25
Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr (2015) 1.25
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther (2011) 1.23
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis (2013) 1.23
Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS (2013) 1.23
Fractures after antiretroviral initiation. AIDS (2012) 1.21
Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther (2011) 1.14
HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr (2012) 1.12
Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc (2013) 1.09
Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis (2010) 1.08
The normal limits, subclinical significance, related metabolic derangements and distinct biological effects of body site-specific adiposity in relatively healthy population. PLoS One (2013) 1.06
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS (2015) 1.05
Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. J Acquir Immune Defic Syndr (2015) 1.05
Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS (2012) 1.03
Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antivir Ther (2012) 1.03
Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr (2012) 1.03
Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J (2010) 0.99
Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.99
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother (2009) 0.99
Age, stress, and isolation in older adults living with HIV. AIDS Care (2013) 0.97
Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J (2003) 0.96
Voiding function in obese and type 2 diabetic female rats. Am J Physiol Renal Physiol (2009) 0.95
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med (2015) 0.95
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS (2012) 0.94
Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther (2012) 0.94
Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis (2011) 0.93
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS (2011) 0.93
Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS (2016) 0.92
A cross-sectional description of age and gender differences in exercise patterns in adults living with HIV. J Assoc Nurses AIDS Care (2014) 0.92
Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol (2013) 0.92
C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.91
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther (2013) 0.91
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS (2016) 0.90
The relationship between patterns of intermittent hypoxia and retinopathy of prematurity in preterm infants. Pediatr Res (2012) 0.89
Omega-3 fatty acids do not improve endothelial function in virologically suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retroviruses (2011) 0.89
Association between depression and coronary artery calcification in women with systemic lupus erythematosus. Rheumatology (Oxford) (2009) 0.88
Osteopenia and osteoporosis in patients with HIV: a review of current concepts. Curr Infect Dis Rep (2006) 0.88
Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr (2004) 0.88
Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis (2016) 0.87
Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS (2014) 0.87
Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS (2010) 0.87
Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol (2013) 0.87
Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS (2014) 0.86
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS (2013) 0.85
Association between depression and vascular disease in systemic lupus erythematosus. J Rheumatol (2011) 0.85
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr (2014) 0.84
Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART. J Int Assoc Physicians AIDS Care (Chic) (2007) 0.84
Frequency of growth hormone deficiency in short statured children. J Coll Physicians Surg Pak (2005) 0.84
Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults. AIDS (2010) 0.83
Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. J Acquir Immune Defic Syndr (2016) 0.82
Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr (2015) 0.82
Pre-operative evaluation of ovarian mass: risk of malignancy index. J Coll Physicians Surg Pak (2004) 0.82
Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Infect Dis Clin North Am (2005) 0.82
Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr (2006) 0.82
Serum leptin values in the healthy obese and non-obese subjects of Rawalpindi. J Pak Med Assoc (2013) 0.82
Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci (2009) 0.81
Precision of Raman spectroscopy measurements in detection of microcalcifications in breast needle biopsies. Anal Chem (2012) 0.81
First reported case of Neisseria meningitidis periorbital cellulitis associated with meningitis. Pediatrics (2005) 0.81
Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults. AIDS (2015) 0.81
Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses (2012) 0.81
Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses (2010) 0.81
Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res (2013) 0.81
Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children. J Ayub Med Coll Abbottabad (2010) 0.81
Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS (2016) 0.80
Cardiovascular disease risk in pediatric HIV: the need for population-specific guidelines. J Acquir Immune Defic Syndr (2011) 0.79
The feasibility, acceptance, and key features of a prevention-focused oral health education program for HIV+ adults. AIDS Care (2013) 0.79
Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals. Curr HIV/AIDS Rep (2014) 0.79
Addition of shear-wave elastography during second-look MR imaging-directed breast US: effect on lesion detection and biopsy targeting. Radiology (2014) 0.79
Spectrum of lipid and lipoprotein indices in human subjects with insulin resistance syndrome. J Ayub Med Coll Abbottabad (2009) 0.79
Rate and predictors of carotid artery intima media thickness progression in antiretroviral-naive HIV-infected and uninfected adults: a 48-week matched prospective cohort study. Antivir Ther (2013) 0.79
Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr (2015) 0.79
Habitual nutrient intake in HIV-infected youth and associations with HIV-related factors. AIDS Res Hum Retroviruses (2014) 0.78
Vitamin D and bone loss in HIV. Curr Opin HIV AIDS (2016) 0.78
Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort. Antivir Ther (2009) 0.78
Protective effects of C-type natriuretic peptide on linear growth and articular cartilage integrity in a mouse model of inflammatory arthritis. Arthritis Rheumatol (2014) 0.78